Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SUSTAIRE vs AMINOPHYLLINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
SUSTAIRE (budesonide/formoterol) is a fixed-dose combination of an inhaled corticosteroid (budesonide) and a long-acting beta2-adrenergic agonist (formoterol). Budesonide exerts anti-inflammatory effects by binding to glucocorticoid receptors, inhibiting inflammatory mediator release, and reducing airway hyperresponsiveness. Formoterol selectively activates beta2-adrenergic receptors in bronchial smooth muscle, causing bronchodilation via increased c AMP production.
Aminophylline is a bronchodilator and respiratory stimulator that acts as a non-selective phosphodiesterase inhibitor, increasing cyclic AMP levels, and as an adenosine receptor antagonist. It also enhances diaphragmatic contractility and mucociliary clearance.
FDA-approved for maintenance treatment of asthma in patients aged 6 years and older,FDA-approved for maintenance treatment of chronic obstructive pulmonary disease (COPD) in adults,Off-label: acute asthma exacerbations (as part of SMART therapy)
Treatment of acute bronchospasm in asthma and COPD,Treatment of apnea of prematurity,Off-label: adjunctive therapy in COPD exacerbations, status asthmaticus
50 mg orally twice daily
Loading dose: 5-6 mg/kg IV over 20-30 minutes (if no recent theophylline). Maintenance: 0.4-0.6 mg/kg/hour IV continuous infusion; oral: 300-600 mg/day divided every 6-8 hours.
Terminal elimination half-life of 8-12 hours in healthy adults; prolonged in renal impairment.
Adults: 7-9 hours (nonsmokers), 4-5 hours (smokers), 10-20 hours (neonates, hepatic impairment, CHF).
Budesonide: extensively metabolized in the liver via CYP3A4 to inactive metabolites; formoterol: partially metabolized via glucuronidation and O-demethylation, with minor CYP involvement.
Hepatic metabolism via CYP1A2 and xanthine oxidase; demethylation and oxidation yield active metabolites (caffeine and 3-methylxanthine).
Primarily renal excretion (80-90% unchanged); minor biliary/fecal elimination (10-20%).
Renal: ~10% unchanged; hepatic metabolism (N-demethylation, oxidation) accounts for >80% of elimination; <1% fecal.
Approximately 95% bound to albumin.
Approximately 40-60% bound to albumin in adults; lower in neonates (20-30%) and patients with hepatic disease.
0.2-0.3 L/kg; indicates limited extravascular distribution primarily in plasma and interstitial fluid.
0.3-0.7 L/kg (average 0.45 L/kg); increased in neonates, cirrhosis, and CHF.
Oral: 70-80% due to first-pass metabolism; intravenous: 100%.
Oral: ~100% (well-absorbed); Rectal: ~80-100% (variable); IM: ~100% (avoid due to pain and unpredictable absorption).
GFR 30-59 m L/min: 50 mg once daily; GFR 15-29 m L/min: 25 mg once daily; GFR <15 m L/min: not recommended
No specific dose adjustment required based on GFR; monitor theophylline levels closely in renal impairment.
Child-Pugh A: 50 mg twice daily; Child-Pugh B: 25 mg twice daily; Child-Pugh C: 12.5 mg once daily
Child-Pugh A: reduce dose by 25%; Child-Pugh B: reduce dose by 50%; Child-Pugh C: reduce dose by 50-75% or consider alternative.
Weight-based: 0.5 mg/kg orally twice daily, max 25 mg per dose
Oral: 5 mg/kg/dose every 6 hours; IV loading: 5-6 mg/kg; maintenance: 0.5-0.9 mg/kg/hour for ages 6 months-9 years, 0.4-0.5 mg/kg/hour for ages 9-16 years.
Age >65 years: initiate at 25 mg twice daily; monitor renal function
Reduce initial dose by 50% (e.g., 0.2-0.3 mg/kg/hour IV) due to decreased clearance; monitor serum theophylline levels and titrate slowly.
Long-acting beta2-adrenergic agonists (LABAs) increase the risk of asthma-related death. SUSTAIRE is contraindicated for use as primary therapy for acute asthma exacerbations. For asthma, use only as add-on therapy for patients not adequately controlled on low-to-medium dose inhaled corticosteroids (ICS) or whose disease severity warrants initiation of ICS and LABA.
No FDA boxed warning exists; however, use caution in patients with acute myocardial injury due to potential arrhythmias.
LABA-associated asthma-related death; cardiovascular effects (tachycardia, hypertension); paradoxical bronchospasm; hypokalemia; hyperglycemia; increased susceptibility to infections; adrenal insufficiency with systemic steroid withdrawal; acute asthma exacerbation management.
Narrow therapeutic index requiring monitoring of serum theophylline levels; increased seizure risk at high concentrations; arrhythmia risk; caution in heart failure, hepatic impairment, and elderly.
Primary treatment of status asthmaticus or acute asthma exacerbations; severe hypersensitivity to any ingredient.
Hypersensitivity to aminophylline, theophylline, ethylenediamine; uncontrolled arrhythmias; active seizure disorder; peptic ulcer; severe hypertension.
No significant food interactions. Grapefruit or grapefruit juice may increase systemic exposure; avoid excessive consumption. No specific dietary restrictions required.
Avoid high-fat meals which can decrease absorption and lead to variable serum levels. Limit caffeine intake (coffee, tea, cola, chocolate) as it may increase theophylline toxicity and side effects. Charcoal-broiled foods and a high-protein, low-carbohydrate diet may increase clearance of theophylline. Consistently maintain dietary habits to avoid fluctuations in theophylline levels.
Pregnancy Category C. First trimester: risk of major malformations unknown, but animal studies show fetal harm. Second/third trimester: potential for fetal respiratory depression, hypotonia, and withdrawal syndrome with chronic use. Avoid use unless benefit outweighs risk.
Aminophylline is a bronchodilator containing theophylline and ethylenediamine. Theophylline crosses the placenta and fetal serum concentrations approximate maternal levels. In the first trimester, limited data do not indicate a significant increase in major malformations, but the drug should be used only if clearly needed. In the second and third trimesters, theophylline may cause fetal tachycardia, jitteriness, and irritability if maternal levels are high. Near term, accumulation of theophylline in the fetus may lead to neonatal withdrawal (irritability, apnea) and transient tachycardia. Risk is dose-dependent and more pronounced at serum levels >15 mcg/m L.
Excreted in breast milk; M/P ratio approximately 0.24. Limited data suggests low infant dose (0.5-1% maternal weight-adjusted dose). Monitor infant for drowsiness and feeding difficulties. Consider risk-benefit.
Theophylline is excreted into breast milk with a milk-to-plasma (M/P) ratio of approximately 0.7. Infant exposure is estimated to be 1–10% of the maternal weight-adjusted dose. Premature infants or those with impaired clearance are at risk for accumulation and toxicity (irritability, jitteriness, feeding intolerance). Breastfeeding is generally considered acceptable if maternal serum levels are within therapeutic range (5-15 mcg/m L) and the infant is monitored for signs of theophylline toxicity. American Academy of Pediatrics classifies theophylline as compatible with breastfeeding, but caution is advised.
No standard dose adjustment recommended. Increased plasma volume may reduce drug levels; monitor clinical response. Avoid near term due to risk of neonatal depression. Use lowest effective dose for shortest duration.
Pregnancy increases the clearance of theophylline by approximately 20-30% due to increased volume of distribution and hepatic metabolism (especially in the second and third trimesters). Doses may need to be increased by 20-30% to maintain therapeutic serum levels. Frequent monitoring of serum theophylline levels (every 1-2 weeks) is recommended to guide dose adjustments. Postpartum, clearance returns to prepregnancy levels within 2-3 months, so doses should be reduced to avoid toxicity.
SUSTAIRE is an inhaled corticosteroid (ICS) used for maintenance treatment of asthma. It is not indicated for acute bronchospasm. Rinse mouth with water after each use to prevent oral candidiasis. Titrate to lowest effective dose to minimize systemic effects. Monitor for growth suppression in children and adrenal insufficiency during stress or prolonged use.
1. Aminophylline is a bronchodilator that is a combination of theophylline and ethylenediamine; the ethylenediamine component may cause allergic reactions in sensitive individuals. 2. Monitor serum theophylline levels closely (therapeutic range: 10-20 mcg/m L); toxicity can occur at levels >20 mcg/m L with symptoms including nausea, vomiting, tachycardia, and seizures. 3. Use with caution in patients with severe hypoxemia, and treat with diltiazem or benzodiazepines for seizures if they occur. 4. Aminophylline can cause significant drug interactions, particularly with cimetidine, fluoroquinolones, and macrolide antibiotics which increase theophylline levels. 5. In acute asthma exacerbations, aminophylline is typically reserved for cases not responding to inhaled beta-agonists and corticosteroids due to narrow therapeutic index.
Use SUSTAIRE regularly as prescribed, not for sudden breathing problems.,Rinse your mouth with water after each use to prevent thrush.,Do not stop taking SUSTAIRE without consulting your doctor, even if you feel better.,Keep track of your symptoms and peak flow if advised.,Seek medical help if your rescue inhaler is not working or you need more puffs than usual.
Take this medication exactly as prescribed; do not chew or crush extended-release tablets.,Avoid consuming large amounts of caffeine (coffee, tea, chocolate, cola) as it may increase side effects such as nervousness and palpitations.,Notify your doctor immediately if you experience nausea, vomiting, irregular heartbeats, or seizures.,Do not smoke or stop smoking without consulting your doctor, as smoking affects how this medication works.,Keep a record of peak flow readings as directed by your healthcare provider.
No interactions on record
"Concurrent administration of aminophylline, a xanthine derivative bronchodilator that is metabolized primarily by CYP1A2 and to a lesser extent CYP3A4, may reduce the clearance of ranolazine, an antianginal agent predominantly metabolized by CYP3A4 and to a lesser extent CYP2D6. Aminophylline can inhibit CYP3A4 activity, leading to increased ranolazine plasma concentrations, which elevates the risk of dose-dependent adverse effects such as QTc prolongation, dizziness, and syncope. This interaction is clinically significant and may necessitate dose adjustment or alternative therapy."
"Asunaprevir, a potent inhibitor of the drug transporter OATP1B1, can significantly decrease the serum concentration of aminophylline, a theophylline salt, likely by reducing its intestinal absorption or increasing its hepatic clearance. This interaction may lead to reduced therapeutic efficacy of aminophylline, potentially worsening respiratory symptoms in patients with asthma or COPD. Close monitoring and dose adjustment of aminophylline are recommended during coadministration with asunaprevir."
"Aminophylline, a bronchodilator, inhibits the metabolism of tibolone, a synthetic steroid hormone used for hormone replacement therapy, primarily through competitive inhibition of cytochrome P450 (CYP) 3A4 isoenzyme. This results in increased plasma concentrations of tibolone and its active metabolites, potentiating its hormonal effects and increasing the risk of adverse events such as thromboembolism, endometrial hyperplasia, or breast tenderness. Clinically, coadministration may require dose adjustments and careful monitoring for signs of estrogenic excess."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SUSTAIRE vs AMINOPHYLLINE, answered by our medical review team.
SUSTAIRE is a Methylxanthine Bronchodilator that works by SUSTAIRE (budesonide/formoterol) is a fixed-dose combination of an inhaled corticosteroid (budesonide) and a long-acting beta2-adrenergic agonist (formoterol). Budesonide exerts anti-inflammatory effects by binding to glucocorticoid receptors, inhibiting inflammatory mediator release, and reducing airway hyperresponsiveness. Formoterol selectively activates beta2-adrenergic receptors in bronchial smooth muscle, causing bronchodilation via increased c AMP production.. AMINOPHYLLINE is a Xanthine Bronchodilator that works by Aminophylline is a bronchodilator and respiratory stimulator that acts as a non-selective phosphodiesterase inhibitor, increasing cyclic AMP levels, and as an adenosine receptor antagonist. It also enhances diaphragmatic contractility and mucociliary clearance.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SUSTAIRE and AMINOPHYLLINE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SUSTAIRE is: 50 mg orally twice daily. The standard adult dose of AMINOPHYLLINE is: Loading dose: 5-6 mg/kg IV over 20-30 minutes (if no recent theophylline). Maintenance: 0.4-0.6 mg/kg/hour IV continuous infusion; oral: 300-600 mg/day divided every 6-8 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SUSTAIRE and AMINOPHYLLINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SUSTAIRE is classified as Category C. Pregnancy Category C. First trimester: risk of major malformations unknown, but animal studies show fetal harm. Second/third trimester: potential for fetal respiratory depression, . AMINOPHYLLINE is classified as Category C. Aminophylline is a bronchodilator containing theophylline and ethylenediamine. Theophylline crosses the placenta and fetal serum concentrations approximate maternal levels. In the . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.